
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health has identified an additional $10 million in annualized cost reductions, which is expected to enhance its financial performance moving forward. The BioReference Health (BRH) unit is close to achieving operational profitability, being only $3 million away from breaking even, excluding non-recurring costs, with full implementation of cost-saving measures anticipated in the latter half of 2025. Furthermore, OPKO is projected to achieve adjusted EBITDA positivity, as indicated by the $5.7 million in depreciation and amortization expense recorded in the first quarter.
Bears say
OPKO Health Inc. reported a disappointing earnings per share (EPS) of -$0.10, falling short of expectations due to non-recurring costs, indicating ongoing financial challenges. Additionally, the performance of the NGENLA segment was particularly concerning, generating only half of anticipated revenue and experiencing a decline compared to the previous year, which raises concerns about market demand and operational effectiveness. Overall, the combination of weak EPS reports and underperformance in key segments creates a negative outlook for the company's financial health and future growth prospects.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares